Severe hypoglycemia is a common acute complication in people with diabetes being treated with insulin.[@b1] Although the prevalence of severe hypoglycemia in insulin-treated type 2 diabetes is generally considered to be lower than in type 1 diabetes, hypoglycemia occurs at clinically significant levels[@b2],[@b3] that increase in frequency with the duration of insulin therapy.[@b1]

Severe hypoglycemia has important implications for diabetes management, quality of life, and costs, both to the patient and the society. A recent survey of older adults in the USA showed that insulins were the second most common medication class associated with hospitalization due to adverse drug events, with hypoglycemia accounting for most of these events.[@b4]

Older patients with type 2 diabetes may be more vulnerable to hypoglycemia because of impaired counter-regulatory responses and awareness of autonomic symptoms.[@b5] In type 2 patients with a history of major macrovascular or microvascular disease or at least one cardiovascular risk factor, severe hypoglycemia is strongly associated with adverse clinical outcomes, such as macrovascular events and death from a cardiovascular course.[@b34] In addition, a history of hypoglycemic episodes severe enough to require hospitalization or emergency department visits is associated with an increase in the risk of dementia.[@b6] Recurrent severe hypoglycemia can also increase the risk of long-term cognitive impairment in children with type 1 diabetes.[@b7]

The long-acting basal insulin analogs, insulin glargine and insulin detemir, which, owing to their improved pharmacokinetics, are able to more closely replicate endogenous 24-h basal insulin secretion, have demonstrated a positive effect on the balance between effective glycemic control and overall hypoglycemia risk compared with protaminated human insulin (neutral protamine Hagedorn \[NPH\] insulin)[@b8]--[@b10]; a trend toward lower risk of severe hypoglycemia has also been observed.[@b10]

The primary aim of this nationwide, retrospective, follow-up study was to evaluate the incidence of hospitalization and secondary healthcare visits due to severe hypoglycemia, hypoglycemic coma, in patients with diabetes, comparing the use of the three available long-acting insulins, NPH insulin, insulin glargine, and insulin detemir, in Finland during 2000--2009. The incidence of childhood type 1 diabetes is very high among this population,[@b11] and prescription bias is minimized by the publicly funded healthcare system,[@b12] which offers full (100%) reimbursement of insulin and oral antidiabetic medicine prescriptions for patients diagnosed with diabetes, and the lack of recommendations regarding insulin preference for specific patient groups.

RESEARCH DESIGN AND METHODS
===========================

Data sources
------------

Data on insulin usage were obtained from the nationwide Finnish Prescription Register, which contains data on reimbursed drugs. Drugs prescribed by a doctor or dentist are partly reimbursed. Special refunds of medicine expenses are paid to patients who have a statement from their doctor attesting to their condition, such as diabetes and need of medication. The Finnish Registry for Reimbursed Medications identifies these patients. Prescription data in the register include the generic name of the drug, the Anatomical Therapeutic Chemical classification system (ATC) code,[@b13] the defined daily dose, and the date of purchase of the reimbursed drug.

Information regarding hospitalization due to severe hypoglycemia (ICD-10 E10.00 for insulin-dependent diabetes with hypoglycemic coma or E11.00 for non-insulin-dependent diabetes with hypoglycemic coma), hereafter referred to as hypoglycemic coma, was obtained from the Finnish Hospital Care Register, which contains data concerning all hospitalization periods and outpatient secondary healthcare visits. All hospitals in Finland are included in this database. From the Finnish Hospital Care Register, we obtained the diagnosis (ICD-10 codes), start and end date of the period, and hospital district. Date and cause of death were obtained from the Finnish Causes of Death Register.[@b14] Unique personal identification numbers are used in all these registers, enabling data to be identified for use in this study.[@b15] Study database was constructed by linking these databases using unique personal identification numbers.

Study population
----------------

A total of 148 482 individuals made at least one insulin purchase (ATC A10A, ATC code of insulins and analogs) between 1 January 2000 and 31 December 2009 in Finland. Of these, 140 034 were entitled to special reimbursement for diabetes indicated by a statement from their doctor; 2003 patients who had reimbursement diagnosis related to diabetes types other than type 1 or 2 and 37 patients who had \<1 day of follow-up time were excluded from the analysis. The resulting study population of 137 994 individuals was stratified into subgroups defined by pre-study and follow-up period: insulin use: naïve (no prior use of study insulins), non-naïve (use of study insulins during a 5-year period before the start of the follow-up study), other (no use of study insulins), and by type of diabetes (type1, type 2, or undefined). Definitions and a schematic representation of the study population are presented in Figure [1](#fig01){ref-type="fig"}.
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We report results on the naïve population (*n* = 75 682) to avoid the many types of biases inherent in observational pharmacoepidemiological studies.[@b16] A new-user design identifies a population of patients with diabetes who have progressed to the stage of the disease no more controlled by other antidiabetic medications and therefore need to initiate basal insulin treatment.

Outcome, exposure, and background variables
-------------------------------------------

The outcome measures of the study were incidence of the first severe hypoglycemic event with coma (codes E10.00 or E11.00 according to the Finnish version of ICD-10) during follow-up, recurrence of hypoglycemic coma, and incidence of all events, as obtained from hospitalizations and secondary care visits.

Current insulin treatment (NPH, insulin detemir, insulin glargine, or other) was used as a time-dependent exposure variable. Further details are given in the Statistical Methods Section.

The following variables evaluated from the baseline period at the start of follow-up were used in the analysis: type of diabetes (type 1, type 2, or undefined), age at the start of follow-up, gender, use of other insulins prior to the start of follow-up, history of hypoglycemia prior to the start of follow-up, calendar year at the start of follow-up, years from diagnosis of diabetes at the start of follow-up, and hospital district. Current use of other insulins, use of sulfonylureas prior to the start of follow-up, current use of sulfonylureas, and switch from one insulin to another during follow-up were used as time-dependent background variables. Other antidiabetic medications were not included as background variables because they are not associated with the risk of severe hypoglycemia.[@b1],[@b2]

The start of follow-up was defined as the date of the first purchase of insulin detemir, glargine, or NPH between 1 January 2000 and 2009 December 31. In Finland, glargine became fully reimbursed in type 1 diabetes in 2003 and detemir in 2005, and both became fully reimbursed in type 2 diabetes in 2007. The time from 1995 until to the start of follow-up was considered as the baseline period. In the analysis of recurrence of hypoglycemic coma, the follow-up started at the end of the first severe hypoglycemic coma episode. The follow-up ended at death, time of the outcome event, or the end of the study period (31 December 2009) whichever came first. In the analysis of all hypoglycemic coma events, the follow-up ended at death or the end of the study period whichever came first.

Statistical methods
-------------------

Crude incidence rates with 95% confidence intervals (CIs) were calculated on the basis of Poisson distribution. To adjust for background variables, a Cox\'s regression model[@b17] was applied, which enabled the follow-up time of each patient to be divided into several periods, allowing adjustments for both baseline variables and time-dependent exposure and other time-dependent variables in the model.

The population was divided into three groups---naïve, non-naïve, and others---according to their use of insulin detemir, insulin glargine, or NPH insulin during (i) history (1995--1999); and (ii) follow-up (2000--2009) as follows:An individual was considered naïve if (s)he had no history of use of detemir, glargine, or NPH and had at least one purchase of detemir, glargine, or NPH during the follow-up.An individual was considered non-naïve if (s)he had history of use of detemir, glargine, or NPH and had at least one purchase of detemir, glargine, or NPH during the follow-up.An individual was classified into others if (s)he had no history of use of detemir, glargine, or NPH and had no purchase of detemir, glargine, or NPH during the follow-up but had purchased some other insulin.

The study population was further divided into three groups, *type 1 diabetes*, *type 2 diabetes*, and *undefined* on the basis of the diagnoses in their reimbursement decisions for diabetes (special refund category 103).

*Drug exposure periods* started from the date of purchase and lasted until the effective length of a drug prescription. The effective length of a prescription was based on the number of defined daily doses contained in the prescription plus a 15% grace period in order to join consecutive drug exposure periods. The current use of detemir, glargine, or NPH at any given time during the follow-up was calculated from these drug exposure periods and used as a time-dependent exposure variable. It was possible that two consecutive drug exposure periods containing different insulins were overlapping. In such a case, we assumed that the patient switched to use another insulin at the time of purchase of the new prescription as it is unlikely for a patient to use two long-acting basal insulins at the same time. It was also possible that a patient did not use any of the insulins at some point, which was denoted by *NO DGN* (no detemir, glargine, or NPH use).

For every patient, a variable, *years from diagnosis*, was calculated as time difference from the minimum of the date of reimbursement decision, first date of purchase of sulfonylureas or insulins until the start of follow-up (as defined previously).

Several sensitivity analyses were performed to investigate the robustness of the findings. We carried out sensitivity analyses by modifying definition of the hypoglycemic coma event as an endpoint.

A subgroup analysis was performed in the populations of patients with type 1 and type 2 diabetes.

RESULTS
=======

The mean follow-up period was 4.1 years, and NPH insulin was the most frequent first insulin for all diagnosis types (Table [1](#tbl1){ref-type="table"}). In total, 9716 severe hypoglycemic events were identified, of which 5669 were first events during the follow-up period (Table [2](#tbl2){ref-type="table"}). Crude incidence rate for the first hypoglycemic coma event (per 100 person-years) was lowest in patients with type 1 diabetes using insulin detemir and highest in patients with type 1 diabetes using insulin NPH. The adjusted risk of the first hypoglycemic coma event was 21.7% (95% CI 9.6--32.1%, *p* \< 0.001) lower for insulin detemir and 9.9% (95% CI 1.5--17.6%, *p* = 0.022) lower for insulin glargine compared with NPH insulin (see Appendix 1 for a detailed description of risk of hypoglycemic coma events). Similarly, the adjusted risk for the recurrence of hypoglycemic coma was 36.3% (95% CI 8.9--55.5%, *p* = 0.014) lower for detemir (versus NPH) and 9.5% (95% CI −10.2 to 25.7%, *p* = 0.318) lower for glargine (versus NPH). Furthermore, the adjusted overall risk for hypoglycemic coma was 30.8% (95% CI 16.2--42.8%, *p* \< 0.001) lower for detemir (versus NPH) and 15.6% (95% CI 5.1--25.0%, *p* = 0.005) lower for glargine (versus NPH). In comparison between detemir and glargine, detemir had a statistically significantly 13.1% (1.0--23.6%), 29.6% (5.1--47.8%), and 17.9% (3.6--30.1%) lower risk for first, recurrent, and overall hypoglycemic coma (*p* = 0.034, *p* = 0.021, and *p* = 0.016), respectively. Patients with type 2 diabetes had statistically significantly 15.5% (2.7--29.9%) and 41.7% (6.7--88.2%) higher risk for first and overall hypoglycemic coma (*p* = 0.016 and *p* = 0.016), respectively, when compared with type 1 diabetes. However, no statistically significant difference was observed for the risk of recurrent hypoglycemic coma between type 1 and type 2 diabetes. Sensitivity analyses for the first and recurrent severe hypoglycemic coma (Appendix 1) showed findings to be robust to the various alternative analysis strategies. The main findings, in absolute and relative risk terms, are presented for the naïve population graphically (Figure [2](#fig02){ref-type="fig"}).

###### 

Basic characteristics of the naïve study population by reimbursement diagnosis (*n* and percentage)

                                                                       Type 1 diabetes   Type 2 diabetes   Undefined   Total
  ------------------------------------------------ ------------------- ----------------- ----------------- ----------- ---------------
  Mean age (years)                                                     26.56             63.33             68.06       58.27
  Gender                                           Male/female (*n*)   7658/4720         27 247/20 679     8077/7301   42 982/32 700
  Male/female (%)                                  61.9/38.1           56.9/43.1         52.5/47.5         56.8/43.2   
  First insulin started                            Detemir             1909              4972              573         7454
                                                   15.4%               10.4%             3.7%              9.8%        
  Glargine                                         3359                12 504            2500              18 363      
                                                   27.1%               26.1%             16.3%             24.3%       
  Neutral protamine Hagedorn                       7110                30 450            12 305            49 865      
                                                   57.4%               63.5%             80.0%             65.9%       
  Years from diagnosis at the start of follow-up   0--1                11 395            12 702            63          24 160
                                                   92.1%               26.5%             0.4%              31.9%       
  1--2                                             191                 3721              61                3973        
                                                   1.5%                7.8%              0.4%              5.2%        
  2--5                                             313                 12 699            607               13 619      
                                                   2.5%                26.5%             3.9%              18.0%       
  5--10                                            350                 15 139            4285              19 774      
                                                   2.8%                31.6%             27.9%             26.1%       
  10+                                              129                 3665              10 362            14 156      
                                                   1.0%                7.6%              67.4%             18.7%       
  Total *n*                                                            12 378            47 926            15 378      75 682

###### 

Incidence of first, recurrent, and all hypoglycemic coma events for insulin detemir, insulin glargine, and NPH insulin, stratified by reimbursement diagnosis

  Diagnosis                            Insulin    Events    Person-years   Rate with 95% confidence interval (per 100 person-years)            
  ------------------------------------ ---------- --------- -------------- ---------------------------------------------------------- -------- --------
  First hypoglycemic coma                                                                                                                      
   Type 1 diabetes                     Glargine   272       18 850         1.443                                                      1.281    1.625
  Detemir                              116        9520      1.218          1.016                                                      1.462    
  NPH                                  454        19 563    2.321          2.117                                                      2.544    
  None/other                           100        6085      1.643          1.351                                                      1.999    
   Type 2 diabetes                     Glargine   660       33 958         1.944                                                      1.801    2.098
  Detemir                              135        10 120    1.334          1.127                                                      1.579    
  NPH                                  1937       96 164    2.014          1.927                                                      2.106    
  None/other                           474        27 375    1.732          1.582                                                      1.895    
   Undefined                           Glargine   268       12 943         2.071                                                      1.837    2.334
  Detemir                              52         2772      1.876          1.430                                                      2.462    
  NPH                                  939        44 507    2.110          1.979                                                      2.249    
  None/other                           262        11 533    2.272          2.013                                                      2.564    
   Total                               Glargine   1200      65 751         1.825                                                      1.725    1.931
  Detemir                              303        22 412    1.352          1.208                                                      1.513    
  NPH                                  3330       160 233   2.078          2.009                                                      2.150    
  None/other                           836        44 993    1.858          1.736                                                      1.988    
  Recurrent hypoglycemic coma events                                                                                                           
   Type 1 diabetes                     Glargine   305       1320           23.109                                                     20.656   25.854
  Detemir                              117        806       14.514         12.108                                                     17.397   
  NPH                                  343        1084      31.651         28.473                                                     35.184   
  None/other                           95         505       18.800         15.375                                                     22.987   
   Type 2 diabetes                     Glargine   469       1967           23.840                                                     21.777   26.099
  Detemir                              82         485       16.910         13.619                                                     20.996   
  NPH                                  1377       4557      30.215         28.660                                                     31.854   
  None/other                           343        1853      18.506         16.648                                                     20.572   
   Undefined                           Glargine   184       1013           18.156                                                     15.713   20.978
  Detemir                              29         283       10.265         7.134                                                      14.772   
  NPH                                  526        2202      23.890         21.933                                                     26.021   
  None/other                           177        964       18.368         15.852                                                     21.283   
   Total                               Glargine   958       4301           22.276                                                     20.909   23.733
  Detemir                              228        1574      14.489         12.726                                                     16.498   
  NPH                                  2246       7843      28.638         27.477                                                     29.847   
  None/other                           615        3322      18.511         17.104                                                     20.033   
  All hypoglycemic coma events                                                                                                                 
   Type 1 diabetes                     Glargine   577       20 185         2.859                                                      2.635    3.102
  Detemir                              233        10 333    2.255          1.983                                                      2.564    
  NPH                                  797        20 672    3.855          3.597                                                      4.133    
  None/other                           195        6599      2.955          2.568                                                      3.400    
   Type 2 diabetes                     Glargine   1129      35 951         3.140                                                      2.962    3.329
  Detemir                              217        10 609    2.045          1.791                                                      2.336    
  NPH                                  3314       100 796   3.288          3.178                                                      3.402    
  None/other                           817        29 285    2.790          2.605                                                      2.988    
   Undefined                           Glargine   452       13 965         3.237                                                      2.952    3.549
  Detemir                              81         3056      2.651          2.132                                                      3.295    
  NPH                                  1465       46 744    3.134          2.978                                                      3.299    
  None/other                           439        12 523    3.506          3.193                                                      3.849    
   Total                               Glargine   2158      70 101         3.078                                                      2.951    3.211
  Detemir                              531        23 998    2.213          2.032                                                      2.409    
  NPH                                  5576       168 212   3.315          3.229                                                      3.403    
  None/other                           1451       48 407    2.997          2.847                                                      3.156    

NPH, neutral protamine Hagedorn.
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When background variables were considered, an increasing risk of first hypoglycemic coma event in older adults compared with the younger population was observed (Table [3](#tbl3){ref-type="table"}). The risk of hypoglycemic coma was also higher in the youngest group of patients (0--9 years). Concomitant use of other insulin types was associated with increased risk of first hypoglycemic coma. The risk of first hypoglycemic coma was slightly lower in women (hazard ratio 0.943, 95% CI 0.894--0.996). History of severe hypoglycemia before the start of follow-up was associated with a greater than fourfold risk of first hypoglycemic coma event (hazard ratio 4.069, 95% CI 3.811--4.344) (Table [3](#tbl3){ref-type="table"}).

###### 

Risk for first hypoglycemic coma estimated by the Cox proportional hazards model

                                                                                         Hazard ratio with 95% confidence interval   *p*-value             
  ------------------------------------------------------------------------ ------------- ------------------------------------------- ----------- --------- -------
  Gender                                                                   Male          (Reference)                                                       
  Female                                                                   0.943         0.894                                       0.996       0.036     
  Age group (years)                                                        0--9          1.378                                       1.113       1.706     0.003
  10--19                                                                   1.097         0.878                                       1.370       0.417     
  20--29                                                                   (Reference)                                                                     
  30--39                                                                   1.223         0.978                                       1.529       0.077     
  40--49                                                                   1.576         1.285                                       1.933       \<0.001   
  50--59                                                                   1.467         1.200                                       1.792       \<0.001   
  60--69                                                                   1.712         1.398                                       2.096       \<0.001   
  70--79                                                                   1.960         1.596                                       2.406       \<0.001   
  80+                                                                      2.183         1.760                                       2.708       \<0.001   
  Use of oral diabetes medication at the start of follow-up                No            (Reference)                                                       
  Yes                                                                      1.063         0.971                                       1.164       0.185     
  Current use of sulfonylureas                                             No            (Reference)                                                       
  Yes                                                                      0.961         0.898                                       1.027       0.240     
  History use of insulins at the start of follow-up                        No            (Reference)                                                       
  Yes                                                                      1.150         1.044                                       1.268       0.005     
  Current use of insulins other than glargine, detemir, and NPH insulins   No            (Reference)                                                       
  Yes                                                                      1.318         1.233                                       1.409       \<0.001   
  History of hypoglycemia                                                  No            (Reference)                                                       
  Yes                                                                      4.069         3.811                                       4.344       \<0.001   
  Switch of insulin                                                        No            (Reference)                                                       
  Yes                                                                      1.109         1.000                                       1.229       0.049     
  Time since diagnosis (years)                                             \<1           (Reference)                                                       
  1--2                                                                     1.057         0.922                                       1.212       0.428     
  2--5                                                                     0.929         0.835                                       1.034       0.176     
  5--10                                                                    0.974         0.875                                       1.085       0.631     
  \>10                                                                     1.117         0.980                                       1.273       0.097     
  Calendar year of the start of follow-up                                  ≤2005         (Reference)                                                       
  2006                                                                     0.749         0.671                                       0.835       \<0.001   
  2007                                                                     0.658         0.584                                       0.742       \<0.001   
  2008                                                                     0.606         0.521                                       0.705       \<0.001   
  2009                                                                     0.460         0.363                                       0.583       \<0.001   

Type of diabetes and current insulin were included in the model.

In subgroup analysis of patients with type 1 and type 2 patients, we found similar differences between the insulins as those reported for the overall population in the risk for the first, recurrent, and overall hypoglycemic coma events in the type 2 diabetes population and in the risk of first hypoglycemic coma event in the type 1 diabetes population (Appendices 2 and 3).

CONCLUSIONS
===========

We compared the incidence of hypoglycemic coma between the long-acting insulins NPH, glargine, and detemir in a large, nationwide, unselected population of people with diabetes in a real-life clinical setting in Finland, where the cost of insulin medication is fully reimbursed. Considerable differences in the absolute risks and statistically significant differences in the adjusted relative risks of the first, recurrent, and overall hypoglycemic events between the use of insulin detemir, glargine, and NPH in the defined population were found. The observed risks for hypoglycemic coma were, in general, lowest with insulin detemir and highest with NPH. In subgroup analyses, these findings were consistent for the risk of first, recurrent, and overall hypoglycemic coma events in patients with type 2 diabetes and for the risk of first hypoglycemic coma in patients with type 1 diabetes.

In randomized controlled trials, both insulin glargine and insulin detemir have consistently shown a reduced incidence of overall and nocturnal hypoglycemia compared with NPH in type 1 and type 2 diabetes.[@b9],[@b18]--[@b23] Clinical trials generally report a very low incidence of severe hypoglycemia. Apart from the small number of events likely to occur in the limited timeframes and cohorts studied in randomized trials, there is also the issue that frequent and/or severe hypoglycemic events are a common exclusion criterion for patients\' eligibility. Furthermore, incidence of severe hypoglycemia increases with longer duration of insulin therapy,[@b1] thus studies focusing on insulin initiation will inevitably underestimate the long-term risk of severe hypoglycemia. Nevertheless, a recent Cochrane review found a trend similar to the findings reported here, with insulin glargine showing a 30% reduction and insulin detemir showing a 50% reduction in overall severe hypoglycemia risk compared with NPH in patients with type 2 diabetes.[@b10]

Compared with clinical trials, fewer hypoglycemic events were reported in routine clinical practice both with insulin glargine and insulin detemir when used as add-on to oral diabetic medications in type 2 diabetes.[@b24] This may be due to several factors. Sulfonylureas were often discontinued when initiating insulin analogs, and the average daily dose of insulin was lower than that used in clinical trials. Observational studies carried out in real-life clinical practice have suggested that significant reductions in severe hypoglycemia can be achieved after switching insulin therapy to insulin detemir in patients with type 1 and type 2 diabetes.[@b24]--[@b27] Non-interventional studies do not have tightly controlled populations or control groups, which limit the certainty with which clinical outcomes can be ascribed to treatment; and hypoglycemic data based on patient recall may be subject to recall bias. However, published results are consistent with the findings of this analysis.

One potential explanation for our finding of reduced hypoglycemic coma risk with insulin detemir or glargine is the decreased day-to-day variability of glucose-lowering action. A pharmacodynamic study in patients with type 1 diabetes injecting identical doses of the insulin in the same injection site once daily for 4 days showed that, compared with NPH, day-to-day variability of glucose-lowering action was 60% and 30% lower with detemir and glargine, respectively.[@b28] In the randomized controlled clinical trials involving patients with type 1 diabetes, insulin detemir was associated with significantly less within-patient fasting blood glucose variability compared with NPH.[@b20],[@b23] We have previously reported an independent association between the variability of fasting plasma glucose and the risk of nocturnal hypoglycemia in type 1 and type 2 diabetes.[@b29]

The reduction in the risk of recurrent hypoglycemic coma was more prominent than the risk of first hypoglycemic coma event for insulin glargine and particularly for insulin detemir compared with NPH. This finding may have significant clinical relevance, as patients suffering from repeated severe hypoglycemic events may be the most vulnerable among patients with diabetes, and thus, there is a need for clinical measures to reduce this risk.

The increasing risk of hospitalization or secondary healthcare visits due to hypoglycemic coma in the older age group is another finding deserving attention. There is a possibility of bias in the data because of older patients with diabetes being less able to manage a severe hypoglycemic event at home than younger patients, but it is important to note that elderly patients may have a greater risk of associated morbidity, for example, cardiovascular events. In the ADVANCE study, severe hypoglycemia was strongly associated with increased risks of adverse clinical outcomes including macrovascular and microvascular events and death[@b30]; the subjects were patients with type 2 diabetes, \>55 years of age. Severe hypoglycemia in the older age groups may also have longer standing consequences; according to a recent study, self-reported history of severe hypoglycemia was associated with age-related cognitive decline.[@b31]

Treatment of hypoglycemic coma can add considerably to healthcare costs. Although difficult to quantify, surveys attempting to assess the impact of providing acute treatment for hypoglycemic events, and subsequent follow-up care, have reported that, irrespective of the national healthcare system surveyed, cases where patients experience severe hypoglycemic events that require hospitalization outweigh all other diabetes-related costs.[@b32],[@b33] Furthermore, the registry-based data presented here may substantially underestimate the actual incidence of all hypoglycemic events. However, incidence of hypoglycemic coma is probably much less underestimated. A recent Finnish population-based survey reported that only 6% of all insulin-treated patients required intensive or emergency treatment for severe hypoglycemia.[@b34] In this study, we had 5669 first events and in population of 75 682, which means that 7.5% of the study population had at least one hypoglycemic coma event during follow-up.

A number of sensitivity analyses were performed to address sources of potential bias and improve the strength of our findings, such as overlapping use of study insulins, different periods of commercial availability of the insulins, selection of the first insulin, and reclassification of no exposure periods; however, several factors must be kept in mind when evaluating results from any observational study on the basis of the record linkage. In this study, the use of prescribed drugs, especially oral antidiabetic medications, could not be verified with certainty and may be subject to misclassification. Although there were many variables included in this study, there was relatively limited information (age, sex, previous hospitalizations, and special refund data) about risk factors connected to hypoglycemia from the available registers. In particular, we had no information about glycemic control during follow-up, and insulins were prescribed empirically and not randomized. It is also unknown which caused the hypoglycemic event, insulin or an underlying disease, when many diabetes-related severity factors are not measured. It is therefore impossible to conclude definitively that there is a causal relationship between current insulin type and outcomes. However, the number of subjects and length of follow-up, plus the robustness of results after performing sensitivity analyses, gives support to the credibility of the results. The use of only naïve, new-insulin-user data reduces bias.[@b16] Non-naïve (prevalent) insulin users are "survivors" of an earlier period of diabetes treatment, which can introduce substantial bias because it is known that the risk connected to the disease varies with time.

HbA~1c~ documentation was not available for this study. The association of more intensive glycemic control with an increased risk of hypoglycemia is well established, and it would have been valuable to adjust the results for HbA~1c~ levels. However, there is no evidence to suggest glycemic control is worse among patients using long-acting insulin analogs; in fact, average HbA~1c~ in insulin-treated patients with type 1 as well as type 2 diabetes in Finland has slightly improved between the years 2000 and 2009.[@b35] Thus, we do not believe the reduced risk of hypoglycemic coma during use of insulin detemir or glargine can be explained by higher average glucose levels.

In conclusion, the real-life data showed considerable differences in risk for hospitalization or secondary healthcare visit due to hypoglycemic coma between insulin detemir, insulin glargine, and NPH insulin in diabetic patients initiating basal insulin therapy during follow-up. Therefore, the risk of hospitalization due to hypoglycemic coma could potentially be modified by the selection of the long-acting insulin.
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KEY POINTS
==========

-   The real-life data showed considerable differences in risk for hospitalization or secondary healthcare visits due to hypoglycemic coma between basal insulin treatments.

-   The risk of hospitalization due to hypoglycemic coma could potentially be modified by the selection of the long-acting insulin.
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